公开(公告)号：USD727167S1

公开(公告)日：2015-04-21

申请号：US29434923

申请日：2012-10-18

Applicant: LEO Pharma A/S

Designer： Alun Wilcox ,  Peter Sprada ,  Graeme Howard Davies ,  Nicholas Henry Reddall ,  Joshua Thomas Richards

公开(公告)号：USD718130S1

公开(公告)日：2014-11-25

申请号：US29434947

申请日：2012-10-18

Applicant: LEO Pharma A/S

Designer： Alun Wilcox ,  Peter Sprada ,  Graeme Howard Davies ,  Nicholas Henry Reddall ,  Joshua Thomas Richards

公开(公告)号：US08759555B2

公开(公告)日：2014-06-24

申请号：US13533405

申请日：2012-06-26

Applicant: Thomas Peter Sabroe ,  Martin John Calverley

Inventor： Thomas Peter Sabroe ,  Martin John Calverley

IPC: C07C401/00 ,  C07D333/72

CPC classification number: C07C401/00 ,  C07C2601/02 ,  C07D333/72

Abstract: The present invention relates to intermediates useful for the synthesis of calcipotriol or calcipotriol monohydrate, to methods of producing said intermediates, and to methods of stereoselectively reducing said intermediates.

Abstract translation: 本发明涉及可用于合成卡泊三醇或卡泊​​三醇一水合物的中间体，制备所述中间体的方法以及立体选择性还原所述中间体的方法。

公开(公告)号：US20130345194A1

公开(公告)日：2013-12-26

申请号：US13977408

申请日：2012-01-06

Applicant: Soren Christian Schou ,  Daniel Rodriquez Greve ,  Simon Feldbæk Nielsen ,  Jens Bjørn Jensen ,  Kevin Neil Dack

Inventor： Soren Christian Schou ,  Daniel Rodriquez Greve ,  Simon Feldbæk Nielsen ,  Jens Bjørn Jensen ,  Kevin Neil Dack

IPC: C07D487/04 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06

Abstract: The invention relates to compounds of general Formula (I), Wherein R1, R2, R3, R4, R5, m, n are defined herein, and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disesase, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.

Abstract translation: 本发明涉及通式（I）的化合物，其中R1，R2，R3，R4，R5，m，n如本文所定义，及其药学上可接受的盐，前体药物，水合物或溶剂化物，单独使用或组合使用 与治疗中的一种或多种其它药物活性化合物一起作为用于预防，治疗或改善疾病及其并发症的JAK激酶和蛋白酪氨酸激酶抑制剂，包括例如牛皮癣，特应性皮炎，酒渣鼻，狼疮，多发性硬化，类风湿性关节炎 ，I型糖尿病，哮喘，癌症，自身免疫性甲状腺疾病，溃疡性结肠炎，克罗恩病，阿尔茨海默氏病，白血病，眼睛疾病如糖尿病性视网膜病变和黄斑变性以及其他自身免疫性疾病和适应症，如免疫抑制在器官 移植。

公开(公告)号：US20130245084A1

公开(公告)日：2013-09-19

申请号：US13989447

申请日：2011-11-21

Applicant: Kristoffer Mansson

Inventor： Kristoffer Mansson

IPC: C07D249/10 ,  C07C317/28 ,  C07C237/34

CPC classification number: C07D249/10 ,  C07C229/46 ,  C07C237/34 ,  C07C317/28 ,  C07C317/44 ,  C07C2601/08

Abstract: Compounds of general formula (I) their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, and methods of treating diseases with said compounds.

Abstract translation: 通式（I）的化合物作为钙受体活性化合物用于预防，治疗或改善与CaSR活性相关的生理障碍或疾病如甲状旁腺功能亢进，包含所述化合物的药物组合物和用于治疗疾病的方法 所述化合物。

公开(公告)号：US08455466B2

公开(公告)日：2013-06-04

申请号：US10532019

申请日：2003-10-23

Applicant: Ernst Torndal Binderup ,  Kai Holst Hansen ,  Claus Aage Svensgaard Bretting ,  Martin John Calverley

Inventor： Ernst Torndal Binderup ,  Kai Holst Hansen ,  Claus Aage Svensgaard Bretting ,  Martin John Calverley

IPC: A61K401/00 ,  C07C31/59

CPC classification number: C07C401/00

Abstract: Compounds according to formula I in which formula R1 and R2, which may be the same or different, represent halogen, (C1-C6)hydrocarbyl, optionally substituted with one or two hydroxyl group or one or more fluorine atoms, or, together with the carbon atom to which they are both attached, R1 and R2 form a (C3-C6)carbocyclic ring, or one of R1 and R2 taken together with R3 forms a direct bond, such that a triple bond is constituted, or R1 and R2 represent both hydrogen; R3 when not forming a direct bond with one of R1 and R2 represents hydrogen or (C1-C3)hydrocarbyl; X represents (E)-ethylene, (Z)-ethylene, ethynylene, or a bond; Y and Z independently represent hydrogen or methyl; and prodrugs and stereo isomeric forms thereof are provided together with their use in therapy, and their use in the manufacture of medicaments.

Abstract translation: 根据式I的化合物，其中可以相同或不同的式R 1和R 2表示卤素，（C 1 -C 6）烃基，任选被一个或两个羟基或一个或多个氟原子取代，或者与 碳原子，R 1和R 2形成（C 3 -C 6）碳环，R 1和R 2中的一个与R 3一起形成直接键，从而构成三键，或者R 1和R 2表示 氢; 当不与R 1和R 2中的一个直接键合时，R 3表示氢或（C 1 -C 3）烃基; X表示（E） - 亚乙基，（Z） - 亚乙基，亚乙炔基或键; Y和Z独立地表示氢或甲基; 并且其前体药物和立体异构形式与其在治疗中的用途一起提供，以及它们在制备药物中的用途。

公开(公告)号：US20130123720A1

公开(公告)日：2013-05-16

申请号：US13703214

申请日：2011-06-10

Applicant: Marianne Lind ,  Gritt Rasmussen ,  Mette Rydahl Sonne ,  Jens Hansen ,  Karsten Petersson

Inventor： Marianne Lind ,  Gritt Rasmussen ,  Mette Rydahl Sonne ,  Jens Hansen ,  Karsten Petersson

IPC: A61K9/12 ,  A61M35/00

CPC classification number: A61K31/593 ,  A61K9/0014 ,  A61K9/122 ,  A61K9/124 ,  A61K31/573 ,  A61K31/58 ,  A61K31/59 ,  A61K47/06 ,  A61K47/08 ,  A61K47/14 ,  A61K47/22 ,  A61M11/00 ,  A61M35/003 ,  A61M2210/04 ,  B65D83/207 ,  B65D83/752 ,  A61K2300/00

Abstract: The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative and a corticosteroid, and its use in the treatment of dermal diseases and conditions. The spray comprises especially a propellant selected from the group consisting of dimethyl ether, diethyl ether and methylethyl ether or a mixture thereof and further a pharmaceutically acceptable lipid carrier solubilised or suspended in said propellant.

Abstract translation: 本发明涉及包含生物活性维生素D衍生物和皮质类固醇的局部喷雾组合物及其在治疗真皮疾病和病症中的用途。 喷雾剂特别包括选自二甲醚，二乙醚和甲基乙基醚或其混合物的推进剂，以及溶解或悬浮在所述推进剂中的药学上可接受的脂质载体。

公开(公告)号：US08338431B2

公开(公告)日：2012-12-25

申请号：US12528649

申请日：2008-02-26

Applicant: Ravindra Babu Bollu ,  Jakob Felding ,  Simon Feldbæk Nielsen ,  Jens Christian Højland Larsen

Inventor： Ravindra Babu Bollu ,  Jakob Felding ,  Simon Feldbæk Nielsen ,  Jens Christian Højland Larsen

IPC: A61K31/497 ,  A61K31/4433 ,  A61K31/382 ,  A61P17/00 ,  A61P35/00 ,  A61P29/00 ,  C07D213/02 ,  C07D491/10 ,  C07D241/10 ,  C07D335/04

CPC classification number: C07D495/10 ,  C07D491/10 ,  C07D493/10

Abstract: The present invention relates to a compound according to formula I, wherein X, A, G, E, R1, R2, R3 are as shown herein; and pharmaceutically acceptable salts, hydrates, N-oxides or solvates hereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Abstract translation: 本发明涉及式I化合物，其中X，A，G，E，R 1，R 2，R 3如本文所示; 及其药学上可接受的盐，水合物，N-氧化物或溶剂合物。 本发明还涉及用于治疗的所述化合物，包含所述化合物的药物组合物，治疗疾病的方法，例如， 所述化合物的皮肤病，以及所述化合物在制备药物中的用途。

公开(公告)号：US20120322776A1

公开(公告)日：2012-12-20

申请号：US13518320

申请日：2010-12-22

Applicant: Karsten Petersson

Inventor： Karsten Petersson

IPC: A61K31/59 ,  A61P17/10 ,  A61P17/06 ,  A61P29/00 ,  A61P17/00

CPC classification number: A61K31/592 ,  A61K9/0014 ,  A61K9/1075 ,  A61K31/593 ,  A61K47/06 ,  A61K47/14 ,  A61K47/18 ,  A61K47/44

Abstract: A pharmaceutical composition comprising a vitamin D derivative or analogue as the active ingredient dissolved in a three-component surfactant-solvent mixture is useful in the treatment of dermal disorders or conditions.

Abstract translation: 包含溶解在三组分表面活性剂 - 溶剂混合物中的作为活性成分的维生素D衍生物或类似物的药物组合物可用于治疗真皮病症或病症。

公开(公告)号：US20120178740A1

公开(公告)日：2012-07-12

申请号：US13382665

申请日：2010-07-08

Applicant: Simon Feldbæk Nielsen ,  Daniel Rodriguez Greve ,  Carsten Ryttersgaard ,  Gunnar Grue-Sørensen ,  Erik Rytter Ottosen ,  Tina Dahlerup Poulsen ,  Søren Christian Schou ,  Anthony Murray

Inventor： Simon Feldbæk Nielsen ,  Daniel Rodriguez Greve ,  Carsten Ryttersgaard ,  Gunnar Grue-Sørensen ,  Erik Rytter Ottosen ,  Tina Dahlerup Poulsen ,  Søren Christian Schou ,  Anthony Murray

IPC: A61K31/55 ,  C07D487/04 ,  A61K31/519 ,  C07D471/04 ,  A61K31/496 ,  A61P37/00 ,  A61P17/00 ,  A61P17/06 ,  A61P19/04 ,  A61P25/00 ,  A61P29/00 ,  A61P3/10 ,  A61P11/06 ,  A61P35/00 ,  A61P1/04 ,  A61P1/00 ,  A61P25/28 ,  A61P35/02 ,  A61P27/02 ,  C07D487/08

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D519/00

Abstract: The invention relates to compounds of general formula (I) wherein A, R1, R2, R3, R4, R5, R9, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.

Abstract translation: 本发明涉及通式（I）的化合物，其中A，R 1，R 2，R 3，R 4，R 5，R 9，m和n如本文所定义，及其药学上可接受的盐，水合物或溶剂化物， 或与一种或多种其它药物活性化合物组合，作为用于预防，治疗或改善疾病及其并发症的JAK激酶和蛋白酪氨酸激酶抑制剂，包括例如牛皮癣，特应性皮炎，酒渣鼻，狼疮，多发性硬化 ，类风湿性关节炎，I型糖尿病，哮喘，癌症，自身免疫性甲状腺疾病，溃疡性结肠炎，克罗恩病，阿尔茨海默病，白血病，眼睛疾病如糖尿病性视网膜病变和黄斑变性以及其他自身免疫性疾病和适应症，其中需要免疫抑制 器官移植的例子。